# P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

> **NCT06014762** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Poseida Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Transformed Follicular Lymphoma (tFL)
- Follicular Lymphoma Grade 3B
- DLBCL
- DLBCL - Diffuse Large B Cell Lymphoma
- DLBCL Arising From Follicular Lymphoma
- DLBCL, Diffused Large B Cell Lymphoma
- DLBCL NOS

## Interventions

- **BIOLOGICAL:** P-CD19CD20-ALLO1
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT06014762
- **Lead sponsor:** Poseida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2029-03
- **Final completion:** 2041-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014762, "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06014762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*